Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04908189 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

Name: A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment — clinical trial record (NCT04908189)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 3

SponsorBristol-Myers Squibb

Started2021-07-15

View on ClinicalTrials.gov ↗

The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA who are naïve to biologic disease modifying antirheumatic drugs or had previously received TNFα inhibitor treatment.The long term extension period will provide additional long-term safety and efficacy information.

Amendment history 1 change detected by DataLookout

2026-09-12

Primary completion pushed: 2024-02-06 → 2024-11-07

Trial Details

NCT Number	NCT04908189
Lead Sponsor	Bristol-Myers Squibb
Conditions	Psoriatic Arthritis
Enrollment	729 participants
Start Date	2021-07-15
Primary Completion	2024-11-07 (estimated)
Study Completion	2026-11-12 (estimated)
Updated on ClinicalTrials.gov	2026-09-11